Detalhe da pesquisa
1.
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
Mov Disord
; 39(2): 350-359, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37886872
2.
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
Mov Disord
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38698639
3.
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.
Mov Disord
; 37(1): 6-15, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34816484
4.
On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Mov Disord
; 36(10): 2244-2253, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363424
5.
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
Mov Disord
; 36(1): 59-63, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026697
6.
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
Mov Disord
; 36(11): 2687-2692, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496081
7.
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease.
Brain
; 143(3): 960-975, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32203581
8.
Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities.
Mov Disord
; 35(10): 1731-1744, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816321
9.
Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
Mov Disord
; 35(6): 1055-1061, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32251552
10.
Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease.
Brain
; 142(6): 1690-1700, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31056668
11.
Do subjects with minimal motor features have prodromal Parkinson disease?
Ann Neurol
; 83(3): 562-574, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420861
12.
Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient.
Ann Neurol
; 81(1): 46-57, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27900791
13.
Levodopa: A new look at an old friend.
Mov Disord
; 33(6): 859-866, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29178365
14.
Huntington's disease: Current and future therapeutic prospects.
Mov Disord
; 33(7): 1033-1041, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29737569
15.
Movement disorder society criteria for clinically established early Parkinson's disease.
Mov Disord
; 33(10): 1643-1646, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30145841
16.
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
Mov Disord
; 32(5): 783-789, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28370340
17.
Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".
Mov Disord
; 36(5): 1281-1282, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991446
18.
Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
Mov Disord
; 31(10): 1489-1496, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27431201
19.
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Mov Disord
; 31(9): 1366-72, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27430123
20.
Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.
Lancet
; 384(9942): 545-55, 2014 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24954676